Abstract
58 patients with advanced carcinoma were treated with a low dose of vincristine followed by 24-hour intravenous infusion of methotrexate. Vincristine enhanced the antineoplastic effect but not the toxicity of methotrexate. In 31 of the 58 patients there was objective regression of the disease. The best results were obtained in head and neck and uterus carcinomas whilst in lung tumors regression was less marked. The method, which was well tolerated by all the patients, is indicated for palliation in advanced tumors or before irradiation in combined chemoradiotherapy.
Get full access to this article
View all access options for this article.
